Complement inhibitors are useful in secondary hemolytic uremic syndromes

Kidney Int. 2019 Oct;96(4):826-829. doi: 10.1016/j.kint.2019.07.006.

Authors

Fernando Caravaca-Fontan¹, Manuel Praga²

Affiliations

¹ Department of Nephrology, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
² Department of Nephrology, Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain; Department of Medicine, Complutense University, Madrid, Spain. Electronic address: mpragat@senefro.org.

PMID: 31543153
DOI: 10.1016/j.kint.2019.07.006

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Clinical Trials as Topic
Complement Activation / drug effects
Complement Activation / immunology
Complement Inactivating Agents / pharmacology
Complement Inactivating Agents / therapeutic use*
Complement Membrane Attack Complex / antagonists & inhibitors*
Complement Membrane Attack Complex / immunology
Drug Administration Schedule
Hemolytic-Uremic Syndrome / drug therapy*
Hemolytic-Uremic Syndrome / immunology
Humans
Kidney Failure, Chronic / immunology
Kidney Failure, Chronic / prevention & control*
Time-to-Treatment
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Complement Inactivating Agents
Complement Membrane Attack Complex
eculizumab